5 speakers









Value creation & financial objectives




Mirjam van Thiel



Acomo is well positioned for long-term value creation

Value creation tree



Entrepreneurial drive Reliability

Act responsibly

Strategic financial objectives

Mid-term value creation objectives

Further building scale in specialty markets

Sales

€ 2 Billion



Delivering a healthy margin



Maintain a strong balance sheet; remain resilient to market changes and manage risks



Remain an attractive dividend payer

Debt / EBITDA

< 2.5

Dividend Payout

> 70%


EBITDA

c. 9%

Proven track record

Sales

Euro million



Total


5 yr CAGR +18%

Excluding M&A

5 yr CAGR +5%

Adjusted EBITDA

Euro million



Total

5 yr CAGR +20%


Excluding M&A

5 yr CAGR +13%

Growth opportunities:

- Organic
- M&A

Growth path towards €2B of Sales



Organic growth | further build scale in specialty markets

Geographic expansion

White space

New markets



Portfolio extension

Included in the

boxes are examples

Size represents share of growth

Existing products

New products

M&A focus areas

| | Europe | Americas |
|---------------------|--|--|
| Spices and Nuts | Priority (bolt on or transformational) | |
| Edible Seeds | | Priority (bolt on or transformational) |
| Organic Ingredients | Priority (bolt on) | |
| Теа | Continue to maximize potential of existing offerings | |
| Food Solutions | Priority (bolt on) | |

M&A Criteria



Active within **plant-based** ingredients within **specialty markets**

Preferably between the €20M – €400M revenue



Finance synergies, and bolt-on revenue and cost synergies

Fit within the **financial framework** of Acomo

If financing with shares, **EPS**accretive in the medium-term




Aligned with **Acomo's core values**: entrepreneurial drive, reliability and act responsible


Further building scale Healthy EBITDA margin Strong balance sheet Attractive dividend

EBITDA% demonstrating the value added role of Acomo

Peer comparison



Opportunity within the portfolio to improve margin



¹ Adjusted EBITDA includes correction for unrealized hedge results and amortization of PPA related to acquisitions. For Organic ingredients, graph reflects 2021/2022 margin when cocoa margins were normal


Capital Allocation Strategy

Strong balance sheet
 Manage volatility
Maintain room to take strategic positions
 Invest in profitable growth
 Invest in capabilities and capacity
 Bolt on and transformational acquisitions
 Dividend
 Attractive dividend ratio

Maintain a strong Balance Sheet


- Healthy solvency ratio's
- Leverage ratio quickly returned to normalised levels post acquisition of Tradin in 2020


Strong solvency ratio Equity / assets 41.1% 42.2% 48.1% 50.7% 2020 2021 2022 2023 2024



Maintain a strong balance sheet


- Working capital as a commercial instrument
- Financial headroom to manage volatility
- Supported by consortium of banks





urther building scale Healthy EBITDA margin Strong balance sheet Attractive dividend

Remain an attractive dividend payer




* 2024 Proposed Dividend

Proven track record

Sales € B





With steady EBITDA at 8% ...

... solid leverage ratio ...

... and attractive dividend payout levels




Proven track record to further accelerate growth





... solid leverage ratio ...

... and attractive dividend payout levels



Key takeaways



Strong base



Growth opportunities, both organic as well as via acquisitions



Financial headroom



Long term shareholder value